High Effectiveness of a 14-Day Concomitant Therapy for Helicobacter pylori Treatment in Primary Care. An Observational Multicenter Study
Olmedo, Llum (Universitat Internacional de Catalunya)
Azagra Ledesma, Rafael ![ORCID Identifier](/img/uab/orcid.ico)
(Universitat Autònoma de Barcelona. Departament de Medicina)
Aguyé Batista, Amada (Institut Català de la Salut)
Pascual Romero, Marta (Universitat Internacional de Catalunya)
Calvet Calvo, Xavier ![ORCID Identifier](/img/uab/orcid.ico)
(Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Gené Tous, Emilio ![ORCID Identifier](/img/uab/orcid.ico)
(Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Date: |
2020 |
Abstract: |
Background: The current cure rates with triple therapy combining a proton-pump inhibitor, amoxicillin and clarithromycin are unacceptably low. Aims: To evaluate the efficacy of a 14-day concomitant therapy as an empirical first-line treatment for curing Helicobacter pylori (Hp) infection in primary care. Methods: Patients from six primary care centers in Catalonia -Spain- were included consecutively. Hp status pre and post treatment was assessed according to local clinical practice protocol. A 14-day concomitant therapy (amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg plus omeprazole 20 mg, all drugs administered twice daily) was prescribed. Adherence to therapy and adverse events were assessed by personal interview. Results: 112 patients were enrolled. Mean age was 46. 7 ± 16. 1 years. Main indication for treatment was non-investigated dyspepsia (83%). Hp eradication was achieved in 100 of the 112 patients. Eradication rates were 89. 3% (95% CI: 81. 7-94. 1) by intention-to-treat (ITT) analysis and 91. 7% (95% CI; 84. 6-95. 9) per protocol (PP). No major side effects were reported; 104 (92. 8%) patients complete the treatment. Forty-seven patients (42%) complained of mild side effects (metallic taste, nausea). Low adherence to treatment (p = 0. 004) and significant adverse events (p = 0. 004) were the variables associated with treatment failure. Conclusions: In primary care, a 14-day concomitant therapy is highly effective and well tolerated. |
Rights: |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. ![Creative Commons](/img/licenses/by.ico) |
Language: |
Anglès |
Document: |
Article ; recerca ; Versió publicada |
Subject: |
Helicobacter ;
Eradication ;
Treatment ;
Concomitant ;
Primary care ;
Multicenter |
Published in: |
Journal of clinical medicine, Vol. 9 (july 2020) , ISSN 2077-0383 |
DOI: 10.3390/jcm9082410
PMID: 32731455
The record appears in these collections:
Research literature >
UAB research groups literature >
Research Centres and Groups (research output) >
Health sciences and biosciences >
Parc Taulí Research and Innovation Institute (I3PTArticles >
Research articlesArticles >
Published articles
Record created 2022-02-07, last modified 2024-06-11